Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer

• Published in: Journal of biomedical science Vol. 17; no. 1; p. 26
• Main Authors: Choi, Jin-Ok, Lee, Mi Hee, Park, Hae-Young, Jung, Sung-Chul
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 16.04.2010; BioMed Central; BMC
• Subjects: Adeno-associated virus; Adeno-associated virus 2; alpha-Galactosidase - genetics; alpha-Galactosidase - metabolism; Analysis; Animals; Biotechnology; Chemical properties; Dependovirus - genetics; Dependovirus - metabolism; Disease; Drug dosages; Enzyme Replacement Therapy; Enzymes; Fabry Disease - therapy; Gene therapy; Gene Transfer Techniques; Genetic research; Genetic Therapy; Genetic Vectors; Hormone therapy; Humans; Medical research; Medicine, Experimental; Mice; Mice, Transgenic; Plasmids; Polymerase chain reaction; Proteins; Studies; Trihexosylceramides - genetics; Trihexosylceramides - metabolism; Veins & arteries; Japan
• ISSN: 1423-0127; 1021-7770; 1423-0127
• DOI: 10.1186/1423-0127-17-26

Enzyme replacement therapy (ERT) with alpha-galactosidase A (alpha-Gal A) is currently the most effective therapeutic strategy for patients with Fabry disease, a lysosomal storage disease. However, ERT has limitations of a short half-life, requirement for frequent administration, and limited efficacy for patients with renal failure. Therefore, we investigated the efficacy of recombinant adeno-associated virus (rAAV) vector-mediated gene therapy for a Fabry disease mouse model and compared it with that of ERT. A pseudotyped rAAV2/8 vector encoding alpha-Gal A cDNA (rAAV2/8-hAGA) was prepared and injected into 18-week-old male Fabry mice through the tail vein. The alpha-Gal A expression level and globotriaosylceramide (Gb3) levels in the Fabry mice were examined and compared with Fabry mice with ERT. Immunohistochemical and ultrastructural studies were conducted. Treatment of Fabry mice with rAAV2/8-hAGA resulted in the clearance of accumulated Gb3 in tissues such as liver, spleen, kidney, heart, and brain with concomitant elevation of alpha-Gal A enzyme activity. Enzyme activity was elevated for up to 60 weeks. In addition, expression of the alpha-Gal A protein was identified in the presence of rAAV2/8-hAGA at 6, 12, and 24 weeks after treatment. alpha-Gal A activity was significantly higher in the mice treated with rAAV2/8-hAGA than in Fabry mice that received ERT. Along with higher alpha-Gal A activity in the kidney of the Fabry mice treated with gene therapy, immunohistochemical studies showed more alpha-Gal A expression in the proximal tubules and glomerulus, and less Gb3 deposition in Fabry mice treated with this gene therapy than in mice given ERT. The alpha-gal A gene transfer significantly reduced the accumulation of Gb3 in the tubules and podocytes of the kidney. Electron microscopic analysis of the kidneys of Fabry mice also showed that gene therapy was more effective than ERT. The rAAV2/8-hAGA mediated alpha-Gal A gene therapy provided improved efficiency over ERT in the Fabry disease mouse model. Furthermore, rAAV2/8-hAGA-mediated expression showed a greater effect in the kidney than ERT.